These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25624711)

  • 21. A patent review of the ubiquitin ligase system: 2015-2018.
    Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
    Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis.
    Lau AW; Fukushima H; Wei W
    Front Biosci (Landmark Ed); 2012 Jun; 17(6):2197-212. PubMed ID: 22652772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting neddylation in cancer therapy.
    Duncan K; Schäfer G; Vava A; Parker MI; Zerbini LF
    Future Oncol; 2012 Nov; 8(11):1461-70. PubMed ID: 23148618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NEDD4: a promising target for cancer therapy.
    Ye X; Wang L; Shang B; Wang Z; Wei W
    Curr Cancer Drug Targets; 2014; 14(6):549-56. PubMed ID: 25088038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy.
    Sampson C; Wang Q; Otkur W; Zhao H; Lu Y; Liu X; Piao HL
    Clin Transl Med; 2023 Mar; 13(3):e1204. PubMed ID: 36881608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance.
    Yang L; Chen J; Huang X; Zhang E; He J; Cai Z
    Am J Med Sci; 2018 Apr; 355(4):368-376. PubMed ID: 29661351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting E3 Ubiquitin Ligases and Deubiquitinases in Ciliopathy and Cancer.
    Shiromizu T; Yuge M; Kasahara K; Yamakawa D; Matsui T; Bessho Y; Inagaki M; Nishimura Y
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ubiquitin proteasome system in immune regulation and therapeutics.
    Bhat SA; Vasi Z; Adhikari R; Gudur A; Ali A; Jiang L; Ferguson R; Liang D; Kuchay S
    Curr Opin Pharmacol; 2022 Dec; 67():102310. PubMed ID: 36288660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway.
    Wang S; Wang X; Gao Y; Peng Y; Dong N; Xie Q; Zhang X; Wu Y; Li M; Li JL
    J Pathol; 2019 Jun; 248(2):204-216. PubMed ID: 30714150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TRIM50 inhibits glycolysis and the malignant progression of gastric cancer by ubiquitinating PGK1.
    Gu C; Xia Y; Lu C; Qiu S; Wang J; Zhang L; Lv J; Jiang T; Fang L; Xu P; Chen Z; Li Y; Xie L; Xu Z; Li B
    Int J Biol Sci; 2024; 20(9):3656-3674. PubMed ID: 38993561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma.
    Yin J; Zhu JM; Shen XZ
    Int J Cancer; 2015 Jan; 136(2):249-57. PubMed ID: 24420637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
    Dou QP; Zonder JA
    Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets.
    Pray TR; Parlati F; Huang J; Wong BR; Payan DG; Bennett MK; Issakani SD; Molineaux S; Demo SD
    Drug Resist Updat; 2002 Dec; 5(6):249-58. PubMed ID: 12531181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cell-based high-throughput screening method based on a ubiquitin-reference technique for identifying modulators of E3 ligases.
    Tian M; Zeng T; Liu M; Han S; Lin H; Lin Q; Li L; Jiang T; Li G; Lin H; Zhang T; Kang Q; Deng X; Wang HR
    J Biol Chem; 2019 Feb; 294(8):2880-2891. PubMed ID: 30587574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].
    Yu Q; Xiong X; Sun Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(1):1-19. PubMed ID: 32621419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Ubiquitin System: An Emerging Therapeutic Target for Lung Cancer.
    Jin JO; Puranik N; Bui QT; Yadav D; Lee PC
    Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the ubiquitin pathway for cancer treatment.
    Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W
    Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of E3 ubiquitin ligases in insulin resistance.
    Yang XD; Xiang DX; Yang YY
    Diabetes Obes Metab; 2016 Aug; 18(8):747-54. PubMed ID: 27097743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation.
    Xu SH; Zhu S; Wang Y; Huang JZ; Chen M; Wu QX; He YT; Chen D; Yan GR
    Cell Death Dis; 2018 May; 9(5):479. PubMed ID: 29706618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the ubiquitin proteasome system in hematologic malignancies.
    Sahasrabuddhe AA; Elenitoba-Johnson KS
    Immunol Rev; 2015 Jan; 263(1):224-39. PubMed ID: 25510280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.